Completed

COMBATImpact of International Travel on the Emergence and Spread of Antimicrobial Resistance in The Netherlands

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
DNA Samples
Who is being recruted

Bacterial Infections and Mycoses+2

+ Bacterial Infections

+ Infections

Over 18 Years
+3 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Ecologic or Community

Assessing exposures and health outcomes at the community level in order to identify population-wide health trends.
Observational
Study Start: November 2012
See protocol details

Summary

Principal SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last updated: August 1, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: November 1, 2012

Actual date on which the first participant was enrolled.

Rationale: Antimicrobial resistance (AMR) among Enterobacteriaceae constitutes an increasingly important human health hazard worldwide. Also in the Netherlands AMR rates have been on the rise in recent years. A limited number of previous studies have suggested high acquisition rates of AMR E. coli during international travel, but information on travel-associated risk factors, duration of colonization and local transmission of imported AMR are largely, if not entirely, lacking. Objectives: Prospectively study the influence of foreign travel and associated risk factors on the acquisition of AMR in the endogenous microbiota of healthy individuals and the subsequent persistence of AMR carriage and transmission to household members of these carriers. Examine whether carriers of resistant Enterobacteriaceae have a higher risk of bacterial infections in the year after travel (compared to non-carriers). Explore the full width of AMR genes and transferable genetic elements acquired during international travel. Study design: multicenter longitudinal cohort study. Study population: healthy, adult (> 18 years) volunteers travelling abroad for 1 week - 3 months. Non travelling household members of these traveling volunteers. Methods: Travelers and non-traveling household members will be recruited at outpatient travel clinics throughout The Netherlands. Faecal samples and questionnaires will be taken before (t=0) travel, immediately after travel (t=1) and 1 month upon return (t = 2). For volunteers that acquire AMR Enterobacteriaceae, repeated questionnaires and faecal samples will be taken after 3, 6 and 12 months. Faecal samples will be cultured to screen for AMR Enterobacteriaceae. Suspected colonies will be identified and susceptibilities confirmed by standard methods. Genotypic characterization of the extended-spectrum betalactamase- (ESBL-) and carbapenemase genes will be performed using microarray and gene sequencing. Clonal bacterial spread within households will be confirmed or excluded by molecular typing. Outcomes: The main outcome measure is the acquisition rate and persistence of AMR in the endogenous microbiota of healthy travelers upon travel. Secondary outcomes are the duration of colonization, the rate of secondary transmission within households, the identification of risk factors, occurrence of self-reported infections in the year following travel and the abundance and type of resistance.

Principal SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Last updated: August 1, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

2215 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Ecologic or Community

These studies look at groups or populations rather than individuals. They explore community-wide exposures and health outcomes to understand public health trends and risks at a broader scale.


Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Bacterial Infections and MycosesBacterial InfectionsInfectionsGram-Negative Bacterial InfectionsEnterobacteriaceae Infections

Criteria

3 inclusion criteria required to participate
age > 18 years

non traveling household members of these traveling volunteers

travelling for > 1 week (7 days) AND < 3 months (90 days)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 3 locations

Academisch Medisch Centrum

Amsterdam, NetherlandsOpen Academisch Medisch Centrum in Google Maps

Maastricht Universitair Medisch Centrum

Maastricht, Netherlands

Erasmus Medisch Centrum

Rotterdam, Netherlands
Completed3 Study Centers